FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

June 3, 2024

https://www.globenewswire.com/news-release/2024/06/03/2892583/33525/en/FibroGen-Announces-Clinical-Trial-Supply-Agreement-with-Regeneron-Pharmaceuticals-to-Evaluate-FibroGen-s-Immuno-Oncology-Assets-FG-3165-anti-Galectin-9-and-FG-3175-anti-CCR8-in-Com.html

SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ:FGEN) today announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate FibroGen’s immuno-oncology assets, FG-3165 and FG-3175, in combination with Regeneron’s anti-PD-1 therapy, LIBTAYO® (cemiplimab), in patients with solid tumors.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.